IT REFERS TO A COMPOUND OF FORMULA I, WHERE: m IS 0-1； A AND B ARE, INDEPENDENT AND DIFFERENT FROM EACH OTHER, HYDROGEN OR A COMPOUND OF FORMULA II； W IS A NITROGENATED HETEROCICLICO； n IS 1-2； R1 IS HALOGEN, C1-4 ALKYL, C1-4 ALCOXY, AMONG OTHERS； R2 IS H, HALOGEN, C1-C4-ALKYL, AMONG OTHERS； R5 IS A COMPOUND OF FORMULA III, WHERE R3 AND R4 ARE, INDEPENDENTLY BETWEEN YES, H, HALOGEN, ALKYL C1-C4, AMONG OTHERS. THEY ARE PREFERRED COMPOUNDS: 1- [4- (4-CHLORO-3-TRIFLUOROMETIL-FENIL) -3,6-DIHIDRO-2H-PIRIDIN-1-IL] -2- [8- (5-FLUORO-PIRIMIDIN-2- IL) -3,8-DIAZA-BICICLO [3.2.1] OCT-3-IL] -ETANONE；6 - (3S, 5R) - 3, 5-dimethyl-4 - [2-oxygen-2 - (2-phenyl-2, 4, 6, 7-tetrahydropyridine [4, 3-C] pyridine-5-il] ethyl] pyridine-1-il；] nicotine； He also mentioned a pharmaceutical composer This compound is an antagonist of p75 receptor and is used to treat bladder hyperactivity.SE REFIERE A UN COMPUESTO DE FORMULA I, DONDE: m ES 0 - 1； A Y B SON, INDEPENDIENTES Y DIFERENTES ENTRE SI, HIDROGENO O UN COMPUESTO DE FORMULA II； W ES UN HETEROCICLICO NITROGENADO； n ES 1-2； R1 ES HALOGENO, ALQUILO C1-4, ALCOXI C1-4, ENTRE OTROS； R2 ES H, HALOGENO, ALQUILO C1-C4, ENTRE OTROS； R5 ES UN COMPUESTO DE FORMULA III, DONDE R3 Y R4 SON, INDEPENDIENTEMENTE ENTRE SI, H, HALOGENO, ALQUILO C1-C4, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: 1-[4-(4-CLORO-3-TRIFLUOROMETIL-FENIL)-3,6-DIHIDRO-2H-PIRIDIN-1-IL]-2-[8-(5-FLUORO-PIRIMIDIN-2-IL)-3,8-DIAZA-BICICLO[3.2.1]OCT-3-IL]-ETANONA； HIDROCLORURO DEL ACIDO 6-{(3S,5R)-3,5-DIMETIL-4-[2-OXO-2-(2-FENIL-2,4,6,7-TETRAHIDROPIRAZOLO[4,3-C]PIRIDIN-5-IL)ETIL]PIPERAZIN-1-IL}NICOTINICO； ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. DICHO COMPUESTO ES UN ANTAGONISTA DEL RECEPTOR P75, UTIL EN EL TRATAMIENTO DE VEJIGA SOBREACTIVA.
